Search Site

Trends banner

ADNOC Drilling H1 revenue $2.37bn

The company posted a net profit of $692m.

Eni profit falls due to dip in oil prices

Q2 net profit fell by 18% to $637 million.

Emirates NBD H1 profit $3.40bn

Total income rose by 12 percent in the same period.

ADIB H1 pre-tax profit $1.08bn

Q2 pre-tax net profit increases by 14 percent.

AstraZeneca to invest $50bn in US

Bulk of funds to go into a Virginia manufacturing center.

Sanofi 2022 net profit at $7.3bn

Sanofi's earnings per share rose by 17.1 percent to US$9 but Sanofi forecast low single-digit growth this year. (AFP)
  • Sanofi is aiming for US$10.9 billion in sales of Dupixent this year.
  • The company's net profit rose by eight percent in 2022.

PARIS, FRANCE – French pharmaceutical giant Sanofi forecast slower earnings growth for 2023 on Friday after profits jumped in 2022 on the back of popular eczema and asthma drug Dupixent.

The company’s net profit rose by eight percent to US$7.3 billion (6.7 billion euros) last year.

Its earnings per share, or profits divided by outstanding shares, rose by 17.1 percent to US$9 (8.26 euros), but Sanofi forecast “low single-digit” growth this year.

Sanofi shares fell following the announcement.

The company’s Dupixent treatment has been a huge success for Sanofi, raking in US$9 billion (8.3 billion euros) in sales last year.

“Dupixent and Vaccines continue to be our leading growth drivers,” Sanofi chief executive Paul Hudson said in a statement.

Sanofi is aiming for US$10.9 billion (10 billion euros) in sales of Dupixent this year.